This is a Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations.

Please visit for more information about this study.

Disease Area

Solid Tumors

Early StageMid StageLate StageCommercial
Early Stage
Mid Stage
Late Stage